GV.PA Genomic Vision SA EURONEXT up 5.88% intraday 11 Mar 2026: heavy volume signals active trade

GV.PA stock is trading at €0.0018 on EURONEXT in Europe after an intraday rise of 5.88% on 11 Mar 2026, led by a volume spike of 38,489,238 shares. The move follows thin liquidity and a low market cap of €693,191, which amplifies intraday swings. Traders should watch the day range €0.0015–€0.0020 and the 50-day average €0.004844 for short-term context. We examine financial metrics, volume drivers, Meyka AI grading, and a model forecast to frame a most-active trading view.

Intraday price and volume action for GV.PA stock

Genomic Vision SA (GV.PA) opened at €0.0018 and hit a day high of €0.0020 and a day low of €0.0015. Volume is 38,489,238, about 2.71x the average daily volume 14,217,513, which marks it among the market’s most active names today.

High relative volume with a tiny market cap (€693,191) typically means price moves are liquidity-driven rather than fundamental. Watch relative volume and order-book depth when trading intraday.

Fundamentals and valuation context for GV.PA stock

Genomic Vision operates in Healthcare, Medical – Diagnostics & Research, with trailing EPS -0.11 and a negative P/E. Revenue per share TTM is 0.0108 and price-to-sales is 0.4684. Book value per share is negative, and the company shows negative free cash flow per share -0.0331.

These ratios show a distressed micro-cap profile. The 50-day average price €0.004844 and 200-day average €0.013997 indicate a prolonged downtrend from the year high €0.094 to the year low €0.0014.

Meyka AI rates GV.PA with a score out of 100 and technical view

Meyka AI rates GV.PA with a score out of 100: Score 62.66 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Technically, GV.PA shows high volatility, a thin order book, and price below the 50- and 200-day averages. For intraday traders, break above €0.0048 would signal improved momentum; failure to hold €0.0015 risks further downside.

Sector and partner context affecting GV.PA stock

Genomic Vision sits in Healthcare where large-cap peers trade on far stronger fundamentals. The company lists strategic agreements with Quest Diagnostics and research ties to Institut Pasteur, which support commercial relevance.

However, sector strength does not automatically lift this micro-cap. Healthcare average P/E is about 30.19, while GV.PA has a negative earnings profile. Investors should separate partnership news from immediate price drivers.

Risk drivers, liquidity and trading strategy for GV.PA stock

Key risks include very low market cap (€693,191), negative equity metrics, and wide swings due to low liquidity. Days-of-inventory and payables metrics suggest operational strain versus peers.

For most-active traders: use tight stops, limit-size exposure, and monitor spreads. Long-term investors need clear revenue or margin improvement before increasing allocation.

Meyka AI’s forecast and price-target scenarios for GV.PA stock

Meyka AI’s forecast model projects a short-to-mid term level of €0.0040, versus the current €0.0018, implying an upside of 122.22%. Forecasts are model-based projections and not guarantees.

Price-target scenarios: conservative €0.0025, base €0.0040, optimistic €0.0100. These targets reflect liquidity risk, partner pipeline, and a recovery toward the 50-day average if operational signs improve.

Final Thoughts

GV.PA stock is trading intraday at €0.0018 on EURONEXT with significant volume (38,489,238) and a 5.88% intraday gain on 11 Mar 2026. The immediate driver is liquidity and active orders rather than a clear fundamental catalyst. Financials show negative EPS -0.11, negative book value, and free cash flow pressure. Meyka AI rates the stock 62.66 (B, HOLD) based on benchmark and sector comparisons and key metrics. For traders, the short-term trade thesis rests on continued high volume and a move above €0.0048 to confirm momentum. For longer-term investors, acceptance of operational and balance-sheet risk is essential before committing capital. Meyka AI’s forecast model projects €0.0040, implying a 122.22% upside from today, but forecasts are model-based projections and not guarantees. We recommend tight risk controls, watch for partnership updates, and follow liquidity signals on the Meyka platform for live order-book context. For live price updates see our GV.PA page on Meyka and market transcripts on Investing.com.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.